Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00661089|
Recruitment Status : Completed
First Posted : April 18, 2008
Results First Posted : February 6, 2012
Last Update Posted : November 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Post-stroke Shoulder Pain and Spasticity||Drug: Botulinum Toxin Type A - OnabotulinumtoxinA Drug: Placebo (Saline)||Not Applicable|
Subjects with shoulder pain and spasticity at the shoulder following a stroke resulting in hemiplegia are eligible for participation. Following an initial screening visit involving a history and physical examination, subjects will be entered in to the study if they have significant spasticity of shoulder internal rotation/adduction associated with pain rated at least a 4 on the VAS for pain. Subjects will also be given a cognitive screening in which they will be asked to rate pain in hypothetical situations.
Shoulder pain is a frequent complication following hemiplegic stroke, and may result in further disability. Spasticity is also a complication following stroke . Botulinum toxin is used in the treatment of post-stroke spasticity and may also have pain modulating effects. Participants in this study will be asked to make total of 6 visits over a period of approximately 13 weeks. Eligible subjects will be randomized to 100 to 200 units of botulinum toxin type injected into the pectoralis major at the second visit. If there is significant spasticity for shoulder extension, subjects will also receive injections into the teres major. Subjects will be followed up with assessments of pain, functioning, active and passive range of motion and depression following the initial injection. At the 12 weeks post injection visit, the blinding will be broken and subjects initially injected with placebo will be injected with the active drug. This will be done to give all subjects an opportunity to receive the active drug, as well as to assess the effects of any differences with delayed treatment. All subjects will return 4 weeks later to repeat the same assessments above. Subjects will be called at one year post study enrollment for repeat pain ratings and for information regarding subsequent treatments.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||"A Randomized Double-Blind Placebo-Controlled Trial of Botulinum Toxin Type A (BOTOX ) in the Treatment of Hemiplegic Shoulder Pain and Spasticity"|
|Study Start Date :||September 2003|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||February 2010|
Experimental: Intramuscular OnabotulinumtoxinA
Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
Drug: Botulinum Toxin Type A - OnabotulinumtoxinA
100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
Other Name: BOTOX
Active Comparator: Intramuscular Placebo (Saline)
Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
Drug: Placebo (Saline)
Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
- Change in Pain Rating From Baseline to Four Weeks [ Time Frame: baseline and four weeks ]Change scores from patient ratings VAS on mm scale for worst pain, averaged over a week for ratings performed at baseline and week four. Scale range 0-100 mm. 0= No pain, 100= worst pain
- Change in Disability Assessment Scale for Hygiene [ Time Frame: baseline and 4 weeks post injection ]Subject rating of scores on the Disability Assessment Scale Range 0-3, 0= no disability, 3= severe disability
- Time to Don a Pull Over Shirt [ Time Frame: 2,4,12, and 16 weeks ]
- Ability to Perform Hygiene Rating [ Time Frame: 2,4,12, and 16 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00661089
|United States, Illinois|
|Rehabilitation Institute of Chicago|
|Chicago, Illinois, United States, 60302|
|Principal Investigator:||Christina Marciniak, MD||Shirley Ryan AbilityLab|